Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor
Children's Hospital Medical Center, Cincinnati
Study ID
NCT07356050
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
6 Months - 6 Years
Healthy Volunteers
Not accepted

Study Details

The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)

Key Dates

Start date
Mar 13, 2025
Status verified
Jan 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
130 participants (estimated)

Arms

  • Arm: Second Measles Vaccine (MV2)
    Participants who receive second measles vaccine.
  • Arm: First Measles Vaccine (MV1)
    Participants who obtain the first measles vaccine.

Primary Outcome Measure

Measles Seroconversion Rates 8 Weeks After MV1 and MV2 Vaccinations [ Time Frame: From enrollment to the end of sample collection at 8 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cincinnati Children's Hospital Medical CenterCincinnatiOhio45229
MacKenzie Tasset
[email protected]
513-803-4856
Charles Quinn, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cincinnati, OH

By condition
Sickle cell disease
By research site
Cincinnati Children's Hospital Medical Center· Cincinnati, OH

Related Studies